Communiqués AlzeCure Pharma AB

Actions

ALZCUR

SE0010133785

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm 10:06:05 21/09/2026			Varia. 5j.	Varia. 1 janv.
7,640 ^SEK	-1,29%		-6,85%	+281,00%

18/09	Mise à jour de la présentation de l'entreprise suite aux accords de collaboration et de licence avec Eli Lilly et QuantumCell	FW
17/09	Novo Nordisk signe un accord de licence de 1,4 milliard de dollars avec Orbis Medicines	MT

Communiqués

18/09	AlzeCure Pharma publishes updated company presentation following the Eli Lilly and QuantumCell agreements	AQ
08/09	AlzeCure Pharma to present at Aktiedagen in Stockholm on September 15	AQ
27/08	AlzeCure Pharma to present at the Pareto Securities 17th Annual Healthcare Conference on September 2	AQ
26/08	AlzeCure publishes its interim report for January – June 2026	AQ
18/08	AlzeCure receives a USD 10 million upfront payment and completes initial transaction with Lilly	AQ
12/08	AlzeCure receives a total upfront payment of USD 12 million and completes the initial transaction with QuantumCell	AQ
03/08	AlzeCure Pharma resolves on a directed share issue to QuantumCell	AQ
02/07	Final Outcome of AlzeCure's Rights Issue	AQ
02/07	Final outcome of AlzeCure’s rights issue	AQ
01/07	AlzeCure Pharma enters an out-licensing and collaboration agreement with QuantumCell ApS for the NeuroRestore ACD856 project	AQ
29/06	Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026	AQ
29/06	Communiqué from the annual general meeting of AlzeCure Pharma on 29 June 2026	AQ
16/06	Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's	AQ
16/06	The subscription period in AlzeCure Pharma's Rights Issue begins today	AQ
10/06	AlzeCure Pharma: From lab to Lilly – A historic USD1bn validation	AQ
09/06	AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project	AQ
09/06	AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project	AQ
05/06	AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document	AQ
26/05	NOTICE TO ANNUAL GENERAL MEETING IN AlzeCure Pharma AB	AQ
19/05	AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain	AQ
13/05	AlzeCure Pharma to present at Redeye Investor Forum Online on May 21	AQ
13/05	AlzeCure Pharma to present at ABG Investor Days on May 21	AQ
08/05	AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856	AQ
06/05	New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain	AQ
05/05	AlzeCure publishes its interim report for January – March 2026	AQ